Clinical Trials | June 01, 2026
Pfizer’s drug combo shows strong survival results in aggressive prostate cancer trial
This marks one of the most closely watched oncology readouts at this year’s medical congress
This marks one of the most closely watched oncology readouts at this year’s medical congress
The company plans to establish similar healthcare centres across universities, schools, and corporate campuses nationwide
Selected ventures to receive grants and structured intellectual property support to strengthen protection and management of healthcare innovations
Aims to bridge transparency gaps in fertility care, with focus on successful patient outcomes, placing healthy live birth outcomes at the centre of treatment journeys
MeziKd delivered stronger response rates across multiple patient groups, including those receiving second- and third-line treatment and patients with higher-risk disease
The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
The study tracked patients for more than five years (median 60.7 months), with protection against disease returning emerging in under four months and continuing long term
The Hyderabad Public School Society celebrates Dr Rao’s journey from HPS Ramanthapur to becoming one of India's leading medical professionals
The findings mark one of the longest progression-free survival outcomes ever reported in advanced lung cancer
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
